KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Tegoprazan-Based Triple Therapy for Helicobacter pylori Eradication: A Phase III Multicenter Randomized Clinical Trial.

Jae Yong Park, Su Jin Hong, Il Ju Choi, Gwang Ho Baik, Sun Moon Kim, Jong-Jae Park, Seong Woo Jeon, Kyung-Oh Kim, Sang Kil Lee, Hwoon-Yong Jung, Jung-Hwan Oh, Chan Hyuk Park, Sang Wook Kim, Ki-Nam Shim, Sam Ryong Jee, Hee Seok Moon, Jeong Seop Moon, Cheol Woong Choi, Wan-Sik Lee, Jae Gyu Kim

Helicobacter 31(1) e70106

PMID41531249
PMCIDPMC12800724
DOI10.1111/hel.70106
发表日期2026-01-14
入排依据:未发现恶性肿瘤人群证据。
已检查 2 张 PubMed Figure,均未识别为 KM 图:FIGURE 1:AI 判定为 flow diagram;FIGURE 2:研究设计图。
摘要

摘要

BACKGROUND: Tegoprazan, a potassium-competitive acid blocker, offers potent and sustained acid inhibition and potentially improves eradication efficacy. AIM: This study aimed to evaluate the efficacy and safety of tegoprazan-based triple therapy with two dosing regimens compared with that of lansoprazole-based therapy for first-line Helicobacter pylori eradication. METHODS: This randomized, double-blind, active-controlled, multicenter trial was conducted at 19 referral hospitals in South Korea (February 2023-April 2024). Treatment-naïve adults with H. pylori infection were randomized 1:1:1 to receive 14-day triple therapy with tegoprazan, 50 mg (TAC1), tegoprazan, 100 mg (TAC2), or lansoprazole, 30 mg (LAC), each combined with amoxicillin 1000 mg and clarithromycin 500 mg, administered twice daily. The primary endpoint was H. pylori eradication rate in the modified intention-to-treat (mITT) population, with a non-inferiority margin of -10%. Secondary endpoints included subgroup analyses based on clarithromycin resistance and safety assessments. RESULTS: Of the 564 screened patients, 382 were randomized. In the mITT analysis (mean age, 54.9 years; 54.3% male), eradication rates were 86.0%, 85.5%, and 78.7% for TAC1, TAC2, and LAC, respectively. Both tegoprazan-based regimens met the non-inferiority criteria. Among clarithromycin-resistant infections, the eradication rates were higher for TAC1 (47.8%) and TAC2 (50.0%) than for LAC (35.5%), although the difference was not statistically significant. Safety profiles were comparable across the groups, with no serious drug-related adverse events. CONCLUSION: Tegoprazan-based triple therapies, at 50- and 100-mg doses, were non-inferior to lansoprazole-based therapy and were well tolerated. Our findings indicated that tegoprazan-based triple therapy is a viable first-line option for H. pylori eradication. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT05933031.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIGURE 1FIGURE 1 Overview of study protocol.
非 KM Figure
FIGURE 2FIGURE 2 Study enrolment, randomization, and treatment allocation. LAC: lansoprazole 30 mg‐based triple therapy; TAC1: tegoprazan 50 mg‐based triple therapy; TAC2: tegoprazan 100 mg‐based triple therapy. All regimens included amoxicillin 1000 mg and clarithromycin 500 mg, administered orally twice daily before meals for 14 days. The modified intention‐to‐treat (mITT) population comprised all randomized participants who met the eligibility criteria and received at least one dose of the study drug. Participants with < 80% treatment compliance (assessed at Visit 3 within Day 15 + 3) were excluded from the per‐protocol set (PPS), along with those with major protocol deviations (e.g., early withdrawal, prohibited medication use). Missing data for Helicobacter pylori eradication were handled as treatment failure in the mITT analyses.
非 KM Figure